MedTrace Logo

A Study Comparing PF-06273340 Immediate Release Tablet, PF-06273340 Modified Release Tablets To PF-06273340 Oral Solution In The Fasted State. This Study Will Also Compare PF-06273340 Modified Release Tablets In Fasted And Fed State

NCT01706796 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 12

Last updated 2013-01-24

No results posted yet for this study

Summary

The primary purpose of this study is to estimate the relative bioavailability and food effect of PF-06273340 tablets.

Conditions

  • Healthy

Interventions

DRUG

PF-06273340

Oral solution, single dose, fasted

DRUG

PF-06273340

Immediate Release Tablet, single dose, fasted

DRUG

PF-06273340

Modified Release Tablet (short duration, MR1), single dose, fasted

DRUG

PF-06273340

Modified Release Tablet (long duration, MR2), single dose, fasted

DRUG

PF-06273340

Modified Release Tablet (short duration, MR1), single dose, fed

DRUG

PF-06273340

Modified Release Tablet (long duration, MR2), single dose, fed

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2012-11-30
Primary Completion
2013-01-31
Completion
2013-01-31

Countries

  • Singapore

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01706796 on ClinicalTrials.gov